EirGenix（6589）株式概要エア・ジェニックス社は、台湾および国際的な開発・製造受託会社として活動している。 詳細6589 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析過去5年間で収益は年間22.8%減少しました。 すべてのリスクチェックを見る6589 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueNT$Current PriceNT$43.70506.9% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-1b2b2016201920222025202620282031Revenue NT$673.6mEarnings NT$86.2mAdvancedSet Fair ValueView all narrativesEirGenix Inc. 競合他社Abnova (Taiwan)Symbol: TWSE:4133Market cap: NT$1.3bHeXun BiosciencesSymbol: TPEX:6986Market cap: NT$2.8bBioLASCO TaiwanSymbol: TPEX:6662Market cap: NT$745.3mWelgene BiotechLtdSymbol: TPEX:6661Market cap: NT$416.0m価格と性能株価の高値、安値、推移の概要EirGenix過去の株価現在の株価NT$43.7052週高値NT$84.3052週安値NT$40.15ベータ0.411ヶ月の変化-10.54%3ヶ月変化n/a1年変化-31.29%3年間の変化-60.45%5年間の変化-72.77%IPOからの変化-2.87%最新ニュースReported Earnings • May 15First quarter 2026 earnings released: NT$0.47 loss per share (vs NT$0.52 loss in 1Q 2025)First quarter 2026 results: NT$0.47 loss per share (improved from NT$0.52 loss in 1Q 2025). Revenue: NT$308.4m (up 70% from 1Q 2025). Net loss: NT$142.2m (loss narrowed 9.5% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings.Reported Earnings • Mar 14Full year 2025 earnings released: NT$2.51 loss per share (vs NT$2.28 loss in FY 2024)Full year 2025 results: NT$2.51 loss per share (further deteriorated from NT$2.28 loss in FY 2024). Revenue: NT$1.01b (flat on FY 2024). Net loss: NT$760.6m (loss widened 8.9% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 23% per year whereas the company’s share price has fallen by 20% per year.お知らせ • Mar 10EirGenix Inc., Annual General Meeting, May 29, 2026EirGenix Inc., Annual General Meeting, May 29, 2026. Location: 2 floor no,8, sec.2 sheng i rd., jhubei city, hsinchu county TaiwanNew Risk • Nov 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.5% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change).Reported Earnings • Nov 15Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2025 results: NT$0.20 loss per share (improved from NT$0.84 loss in 3Q 2024). Revenue: NT$229.0m (down 7.7% from 3Q 2024). Net loss: NT$60.3m (loss narrowed 77% from 3Q 2024). Revenue missed analyst estimates by 23%. Earnings per share (EPS) exceeded analyst estimates by 67%. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.Reported Earnings • Aug 17Second quarter 2025 earnings: EPS and revenues miss analyst expectationsSecond quarter 2025 results: NT$1.23 loss per share (further deteriorated from NT$0.72 loss in 2Q 2024). Revenue: NT$230.6m (down 6.4% from 2Q 2024). Net loss: NT$370.8m (loss widened 68% from 2Q 2024). Revenue missed analyst estimates by 7.4%. Earnings per share (EPS) also missed analyst estimates by 137%. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.最新情報をもっと見るRecent updatesReported Earnings • May 15First quarter 2026 earnings released: NT$0.47 loss per share (vs NT$0.52 loss in 1Q 2025)First quarter 2026 results: NT$0.47 loss per share (improved from NT$0.52 loss in 1Q 2025). Revenue: NT$308.4m (up 70% from 1Q 2025). Net loss: NT$142.2m (loss narrowed 9.5% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings.Reported Earnings • Mar 14Full year 2025 earnings released: NT$2.51 loss per share (vs NT$2.28 loss in FY 2024)Full year 2025 results: NT$2.51 loss per share (further deteriorated from NT$2.28 loss in FY 2024). Revenue: NT$1.01b (flat on FY 2024). Net loss: NT$760.6m (loss widened 8.9% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 23% per year whereas the company’s share price has fallen by 20% per year.お知らせ • Mar 10EirGenix Inc., Annual General Meeting, May 29, 2026EirGenix Inc., Annual General Meeting, May 29, 2026. Location: 2 floor no,8, sec.2 sheng i rd., jhubei city, hsinchu county TaiwanNew Risk • Nov 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.5% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change).Reported Earnings • Nov 15Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2025 results: NT$0.20 loss per share (improved from NT$0.84 loss in 3Q 2024). Revenue: NT$229.0m (down 7.7% from 3Q 2024). Net loss: NT$60.3m (loss narrowed 77% from 3Q 2024). Revenue missed analyst estimates by 23%. Earnings per share (EPS) exceeded analyst estimates by 67%. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.Reported Earnings • Aug 17Second quarter 2025 earnings: EPS and revenues miss analyst expectationsSecond quarter 2025 results: NT$1.23 loss per share (further deteriorated from NT$0.72 loss in 2Q 2024). Revenue: NT$230.6m (down 6.4% from 2Q 2024). Net loss: NT$370.8m (loss widened 68% from 2Q 2024). Revenue missed analyst estimates by 7.4%. Earnings per share (EPS) also missed analyst estimates by 137%. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.Major Estimate Revision • Jun 21Consensus revenue estimates fall by 39%The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from NT$2.42b to NT$1.49b. Forecast losses increased from -NT$0.68 to -NT$0.90 per share. Life Sciences industry in Taiwan expected to see average net income growth of 19% next year. Consensus price target down from NT$128 to NT$117. Share price rose 5.5% to NT$65.50 over the past week.Price Target Changed • Jun 21Price target decreased by 8.6% to NT$117Down from NT$128, the current price target is an average from 2 analysts. New target price is 78% above last closing price of NT$65.50. Stock is down 24% over the past year. The company is forecast to post a net loss per share of NT$0.90 next year compared to a net loss per share of NT$2.28 last year.Reported Earnings • May 15First quarter 2025 earnings released: NT$0.52 loss per share (vs NT$0.34 loss in 1Q 2024)First quarter 2025 results: NT$0.52 loss per share (further deteriorated from NT$0.34 loss in 1Q 2024). Revenue: NT$181.9m (down 17% from 1Q 2024). Net loss: NT$157.1m (loss widened 51% from 1Q 2024). Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance.お知らせ • May 06EirGenix Inc. to Report Q1, 2025 Results on May 13, 2025EirGenix Inc. announced that they will report Q1, 2025 results at 2:30 PM, Taipei Standard Time on May 13, 2025お知らせ • Apr 07+ 1 more updateEirGenix Inc. Officially Submits the Phase III Clinical Trial Application of EG1206A to the Health Authority of GeorgiaEirGenix has officially submitted the Phase III clinical trial application of EG1206A to the health authority of Mexico. New drug name or code: EG1206A (pertuzumab biosimilar). Indication: Early breast cancer (EBC) and metastatic breast cancer (MBC). Planned development stages: (1) IND: Completed, (2) Phase I: Completed, (3) Phase III: Multi countries, multi centers study, (4) BLA/MAA: Not yet started. Current development stage: (1) Application submission/approval/disapproval/each of clinical trials (include interim analysis): USFDA & TFDA agreed EirGenix to proceed the Phase III clinical trial of EG1206A (pertuzumab biosimilar). EirGenix has officially submitted the Phase III clinical trial application of EG1206A to the regulatory authority of Mexico-COFEPRIS (Comision Federal para la Proteccion contra Riesgos Sanitarios). After obtaining official approval or the results of statistically significant sense, the future strategy: After completing the Phase III clinical trial for the developmental product EG1206A (pertuzumab biosimilar), the Company will submit a marketing application to regulatory agency. Accumulated investment expenditure incurred: The information may affect the licensing deal during the future international negotiation. To protect the rights and interests of the Company and investors, it will not be disclosed publicly. Upcoming development plan: (1) Estimated date of completion: The actual completion time will depend on the regulatory agency review and the progress of trial enrollment. The Company will disclose relevant information in accordance with regulations. Market situation: According to Roche's annual report of FY2024, global sales of Perjeta totaled CHF 3.616 billion (around USD 4.003 billion) in FY2024.Reported Earnings • Mar 19Full year 2024 earnings: EPS and revenues exceed analyst expectationsFull year 2024 results: NT$2.28 loss per share (improved from NT$3.00 loss in FY 2023). Revenue: NT$1.01b (down 1.3% from FY 2023). Net loss: NT$698.3m (loss narrowed 24% from FY 2023). Revenue exceeded analyst estimates by 13%. Earnings per share (EPS) also surpassed analyst estimates by 13%. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance.お知らせ • Mar 13+ 2 more updatesEirGenix Inc., Annual General Meeting, Jun 13, 2025EirGenix Inc., Annual General Meeting, Jun 13, 2025. Location: 1 floor no,102 ln.169, k`ang ning st., sijhih district, new taipei city Taiwanお知らせ • Mar 05EirGenix Inc. to Report Fiscal Year 2024 Results on Mar 12, 2025EirGenix Inc. announced that they will report fiscal year 2024 results on Mar 12, 2025New Risk • Jan 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (NT$454m net loss in 2 years). Share price has been volatile over the past 3 months (6.1% average weekly change).お知らせ • Jan 24USFDA Issues Study May Proceed Letter to EirGenix for the Phase III Clinical Trial of Developmental Product Eg1206a (Pertuzumab Biosimilar)EirGenix Inc. announced that it has issued a study may proceed letter to EirGenix for the Phase III clinical trial of EG1206A (pertuzumab biosimilar). Indication: Early breast cancer (EBC) and metastatic breast cancer (MBC). Planned development stages: IND: Completed (2) Phase I: Completed Phase III: The USFDA has issued a study may proceed Letter to EirGenix for The Phase III clinical trial of the developmental product EG1206A (pertizumab biosimilar). BLA/MAA: Not yet started. Current development stage: Application submission/approval/approval/disapproval/each of clinical trials (include interim analysis): The USFDA has issuing a study may proceed letter toEirGenix for the Phase II clinical trial of the developmental productEG1206A (pertuzUMab biosimilar). Once disapproved by competent authority or each of clinical trials (include interim analysis) results less than statistically significant sense, the risks & the associated measures the Company may occur: After completing the Phase III clinical trial of the Development product EG1206A (expertuzumab biosimilar). The Company will submit a marketing application to regulatory agency (4) Accumulated investment expenditure incurred: The information may affect the licensing deal during the future international negotiation. To protect the rights and interests of the Company and investors, it will not be disclosed publicly. Upcoming development plan: Estimated date of completion: The actual completion time will depend on the regulatory agency review and the progress of trial enrollment. The Company will disclose relevant information in accordance with regulations. Estimated responsibilities: None.お知らせ • Jan 06EirGenix, Inc. Officially Submits NDA for the Biosimilar Drug EIRGASUN of 420 Mg Lyophilized Powder for Intraous Administration to the TFDAEirGenix Inc., has officially submitted NDA for the biosimilar drug EIRGASUN of 420 mg lyophilized powder for intravenous administration to the TFDA. New drug name or code: EG12014 (EIRGASUN) (trastuzumab biosimilar). Indication: The treatment of HER2 overexpressing early breast cancer, metastatic breast cancer and metastatic gastric cancer. Planned development stages: This application pertains to the registration of a previously approved biological product with different strength and packaging from different manufacturing sites. The drug product manufacturing facility is Formosa Laboratories Inc. and TFDA is currently reviewing status after the GMP inspection. Current development stage: Application submission/approval/disapproval/each of clinical trials (include interim analysis): Submit New Drug Application (NDA) for EIRGASUN 420 mg lyophilized powder for intravenous administration to the Taiwan Food and Drug Administration (TFDA). After obtaining official approval or the results of statistically significant sense, the future strategy: Once EG12014 420 mg lyophilized powder for intravenous administration is approved in Taiwan, it will have a positive impact on EirGenix's business operation in the future. Accumulated investment expenditure incurred: It was agreed not to disclose this information publicly to protect the company and investors' rights according to the signed confidentiality agreement with Sandoz AG. Upcoming development plan: Estimated date of completion: The review time is based on the process of TFDA. The actual review and approval time are the decision of the TFDA and are subject to the official notification of the TFDA.お知らせ • Dec 26EirGenix Inc. Officially Submits the Phase III Clinical Trial Application for the Developmental Product EG1206A (pertuzumab Biosimilar) in US FDAEirGenix has officially submitted the Phase III clinical trial application for the developmental product EG1206A (pertuzumab biosimilar) in US FDA. Early breast cancer (EBC) and metastatic breast cancer (MBC) 4.Planned development stages: (1) IND: Completed (2) Phase I: Completed (3) Phase III: EirGenix has officially submitted Phase III clinical trial application in US FDA. (4) BLA/MAA: Not yet started. 5.Current development stage: (1)Application submission/approval/disapproval/each of clinical trials (include interim analysis): EirGenix has officially submitted Phase III clinical trial application in US FDA. (2)Once disapproved by competent authority or each of clinical trials (include interim analysis) results less than statistically significant sense, the risks & the associated measures the Company may occur: N/A (3)After obtaining official approval or the results of statistically significant sense, the future strategy: After completing the Phase III clinical trial for the developmental product EG1206A (pertuzumab biosimilar), the company will submit a marketing application to regulatory agency.New Risk • Dec 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (NT$480m net loss in 2 years). Share price has been volatile over the past 3 months (6.3% average weekly change).Major Estimate Revision • Dec 12Consensus revenue estimates fall by 16%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from NT$1.07b to NT$895.0m. Forecast losses increased from -NT$1.94 to -NT$2.61 per share. Life Sciences industry in Taiwan expected to see average net income growth of 50% next year. Consensus price target down from NT$120 to NT$115. Share price fell 20% to NT$73.50 over the past week.Reported Earnings • Nov 15Third quarter 2024 earnings: EPS exceeds analyst expectationsThird quarter 2024 results: NT$0.84 loss per share (further deteriorated from NT$0.37 loss in 3Q 2023). Revenue: NT$248.2m (up 17% from 3Q 2023). Net loss: NT$256.1m (loss widened 129% from 3Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.3%. Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.お知らせ • Nov 05EirGenix Inc. to Report Q3, 2024 Results on Nov 12, 2024EirGenix Inc. announced that they will report Q3, 2024 results on Nov 12, 2024Reported Earnings • Aug 17Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2024 results: NT$0.72 loss per share (further deteriorated from NT$0.64 loss in 2Q 2023). Revenue: NT$246.4m (up 78% from 2Q 2023). Net loss: NT$220.6m (loss widened 14% from 2Q 2023). Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) missed analyst estimates by 2.9%. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.お知らせ • Aug 01EirGenix Inc. to Report Q2, 2024 Results on Aug 08, 2024EirGenix Inc. announced that they will report Q2, 2024 results on Aug 08, 2024Major Estimate Revision • May 30Consensus revenue estimates fall by 28%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from NT$2.29b to NT$1.64b. Forecast loss of -NT$1.00, down from profit of NT$1.09 per share profit previously. Life Sciences industry in Taiwan expected to see average net income growth of 39% next year. Consensus price target down from NT$133 to NT$113. Share price was steady at NT$79.10 over the past week.Breakeven Date Change • May 29No longer forecast to breakevenThe analyst covering EirGenix no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of NT$65.0m in 2024. New forecast suggests the company will make a loss of NT$413.0m in 2025.Reported Earnings • May 18First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2024 results: NT$0.34 loss per share (improved from NT$0.67 loss in 1Q 2023). Revenue: NT$219.7m (up 1.6% from 1Q 2023). Net loss: NT$104.0m (loss narrowed 49% from 1Q 2023). Revenue missed analyst estimates by 3.6%. Earnings per share (EPS) exceeded analyst estimates by 42%. Revenue is forecast to grow 47% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.お知らせ • May 02EirGenix Inc. to Report Q1, 2024 Results on May 09, 2024EirGenix Inc. announced that they will report Q1, 2024 results on May 09, 2024Breakeven Date Change • Apr 23Forecast breakeven date pushed back to 2025The analyst covering EirGenix previously expected the company to break even in 2024. New forecast suggests the company will make a profit of NT$413.0m in 2025. Average annual earnings growth of 144% is required to achieve expected profit on schedule.Reported Earnings • Mar 26Full year 2023 earnings: EPS misses analyst expectationsFull year 2023 results: NT$3.00 loss per share (further deteriorated from NT$0.38 loss in FY 2022). Revenue: NT$1.02b (down 31% from FY 2022). Net loss: NT$915.2m (loss widened NT$799.7m from FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 67%. Revenue is forecast to grow 45% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.お知らせ • Mar 09EirGenix Inc., Annual General Meeting, May 30, 2024EirGenix Inc., Annual General Meeting, May 30, 2024, at 09:30 Taipei Standard Time. Location: International Conference Hall, R&D Center, Hsinchu Biomedical Park 2F, No. 8, Sec. 2, Shengyi Rd., Zhubei City, Hsinchu County Zhubei Taiwan Agenda: To consider Report the business results of 2023; to Audit Committee’s review report; to The 2023 implementation report for the sound business plan; to Amendment to the Regulations Governing Procedure for Board of Directors Meetings; to Discontinue the Private Security Offering Approved by 2023 Shareholders' Meeting; to Remuneration policy for the directors of 2023; to Accept 2023 financial statements and business report; to Ratification of the 2023 deficit offset proposal; and to consider other matters if any.Major Estimate Revision • Feb 06Consensus revenue estimates fall by 18%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from NT$1.24b to NT$1.02b. Forecast losses increased from -NT$0.89 to -NT$1.80 per share. Life Sciences industry in Taiwan expected to see average net income growth of 28% next year. Consensus price target down from NT$155 to NT$133. Share price was steady at NT$91.80 over the past week.Price Target Changed • Feb 05Price target decreased by 16% to NT$133Down from NT$158, the current price target is an average from 2 analysts. New target price is 44% above last closing price of NT$91.80. Stock is down 23% over the past year. The company is forecast to post a net loss per share of NT$1.80 next year compared to a net loss per share of NT$0.38 last year.お知らせ • Nov 23EirGenix Inc.'s Breast Cancer Biosimilar Receives Marketing Authorization by ECEirGenix Inc. announced that its trastuzumab biosimilar medicine (EG12014) which their commercial partner Sandoz plans to commercialize (150 mg, for intravenous use) had received a marketing authorization from the European Commission (EC). The marketing authorization in the EU will cover the treatment of human epidermal growth factor receptor 2 positive (HER2-positive) breast cancer and metastatic gastric cancers, which are the same indications approved by the EC for the reference biologic, Herceptin(R). Sandoz AG and EirGenix signed a license agreement in April 2019. Under this agreement, EirGenix Inc. will remain responsible for the development and manufacturing of trastuzumab while Sandoz will hold the rights to commercialize the medicine upon approval in the global market (excluding Taiwan, China, Russia, and some Asian countries). Breast and gastric cancers are among the most frequently occurring in Europe, and combined, are responsible for nearly 200,000 deaths annually. Biosimilars have enormous potential to improve cancer care by substantially increasing access to these critical medicines. The impact of both breast and gastric cancer in Europe is significant. Each year, over 355,000 women are diagnosed with breast cancer, and with 92,000 deaths per year, it is the number one cause of cancer death among women. Gastric cancer is the sixth most common of all cancer types and with 107,000 deaths annually it is the fourth most common cause of cancer-related death in Europe. In up to 20% of breast cancers and up to 30% of gastric cancers diagnosed, a HER2 protein overexpression (or HER2 gene amplification) is detected resulting in an uncontrollable growth and division of cells. HER2 cancers are particularly aggressive cancer types that respond well to targeted treatment. The authorisation of EG12014 in Europe expands access to a vital, high-quality treatment for breast and gastric cancers helping to ease the burden of these diseases on patients and delivering important savings for healthcare systems to ensure sustainability. EirGenix's trastuzumab bios biosimilar drug (EG12014) (150 mg lyophilized powder for injection) also received market approval by TFDA in June. The application of the health insurance pricing was approved by the National Health Insurance Administration under the Ministry of Health and Welfare in mid-September, paving the way for the formal launch of the product in Taiwan. EirGenix develops a series of HER2-positive breast cancer product combinations, including the second- generation HER2-positive targeted antibody drug Perjeta(R) (Pertuzumab), which are continuously advancing into the Phase III clinical trial. With the successful market introduction of the products, further market expansion and strengthening of the product's international competitive advantage will be realized.Reported Earnings • Nov 15Third quarter 2023 earnings: EPS exceeds analyst expectationsThird quarter 2023 results: NT$0.37 loss per share (further deteriorated from NT$0.091 loss in 3Q 2022). Revenue: NT$211.5m (down 42% from 3Q 2022). Net loss: NT$111.7m (loss widened 305% from 3Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 25%. Revenue is forecast to grow 51% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth.Breakeven Date Change • Nov 15The 2 analysts covering EirGenix previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of NT$113.0m in 2024.お知らせ • Sep 20National Health Insurance Administration Approves EirGenix Inc.'S Biosimilar, Eirgasun Vial 150 Mg to Be Enrolled in the Reimbursement SystemEirGenix Inc.'s biosimilar, Eirgasun vial 150 mg, has been approved by National Health Insurance Administration, Ministry of Health and Welfare to be enrolled in the reimbursement system, it is officially effective from October 1, 2023. Usage: The treatment of HER2 overexpressing early breast cancer, metastatic breast cancer, and metastatic gastric cancer. The price paid is TWD 11,323 per vial at the current market price.Reported Earnings • Aug 10Second quarter 2023 earnings: EPS and revenues miss analyst expectationsSecond quarter 2023 results: NT$0.64 loss per share (down from NT$0.021 profit in 2Q 2022). Revenue: NT$138.3m (down 59% from 2Q 2022). Net loss: NT$194.1m (down NT$200.5m from profit in 2Q 2022). Revenue missed analyst estimates by 63%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 66% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.Price Target Changed • Jun 09Price target decreased by 7.5% to NT$172Down from NT$186, the current price target is an average from 2 analysts. New target price is 57% above last closing price of NT$110. Stock is up 25% over the past year. The company is forecast to post a net loss per share of NT$0.13 next year compared to a net loss per share of NT$0.38 last year.Reported Earnings • Mar 21Full year 2022 earnings: Revenues and EPS in line with analyst expectationsFull year 2022 results: NT$0.38 loss per share (further deteriorated from NT$0.17 loss in FY 2021). Revenue: NT$1.48b (down 13% from FY 2021). Net loss: NT$115.5m (loss widened 171% from FY 2021). Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has only increased by 64% per year, which means it is significantly lagging earnings growth.Price Target Changed • Mar 15Price target decreased by 9.8% to NT$175Down from NT$194, the current price target is an average from 2 analysts. New target price is 55% above last closing price of NT$113. Stock is up 23% over the past year. The company is forecast to post a net loss per share of NT$0.18 next year compared to a net loss per share of NT$0.18 last year.お知らせ • Jan 12EirGenix Inc. Announces Executive ChangesEirGenix Inc. announced that Chun-Fu Lu, Chairman, Foxconn Technology Co. Ltd., has replaced Jih-Luh Tang as Representative of Juristic Person as Director, effective January 10, 2023.Breakeven Date Change • Dec 31Forecast breakeven date pushed back to 2023The 2 analysts covering EirGenix previously expected the company to break even in 2022. New consensus forecast suggests the company will make a profit of NT$710.0m in 2023. Average annual earnings growth of 105% is required to achieve expected profit on schedule.お知らせ • Dec 29Eirgenix Inc. Announces Establishment of Corporate Governance CommitteeEirGenix Inc. announced the establishment of the company's Corporate Governance Committee with Lee-Cheng Liu: President & CEO, EirGenix, Inc; Ming-Thaur Chang: Independent Director, DBS Bank (Taiwan) Ltd.; Fu-Shiow Yin: Independent Director, Foresee Pharmaceuticals Co. Ltd.; Ming-Shen Chen: Professor of Finance at National Taiwan University.; and Po-Chih Chen: Senior Advisors to the President, effective December 28, 2022. Mr. Ming-Shen Chen is the chairman of first term Corporate Governance Committee.Price Target Changed • Nov 29Price target increased to NT$169Up from NT$156, the current price target is an average from 2 analysts. New target price is 27% above last closing price of NT$133. Stock is up 20% over the past year. The company is forecast to post earnings per share of NT$0.02 next year compared to a net loss per share of NT$0.18 last year.Reported Earnings • Nov 16Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: NT$0.09 loss per share (down from NT$1.36 profit in 3Q 2021). Revenue: NT$361.6m (down 45% from 3Q 2021). Net loss: NT$27.6m (down 108% from profit in 3Q 2021). Revenue exceeded analyst estimates by 7.3%. Earnings per share (EPS) also surpassed analyst estimates by 70%. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has only increased by 68% per year, which means it is significantly lagging earnings growth.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 6 non-independent directors. Independent Director Po-Chih Chen was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 13Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: NT$0.09 loss per share (down from NT$1.36 profit in 3Q 2021). Revenue: NT$361.6m (down 45% from 3Q 2021). Net loss: NT$27.6m (down 108% from profit in 3Q 2021). Revenue exceeded analyst estimates by 7.3%. Earnings per share (EPS) also surpassed analyst estimates by 70%. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has only increased by 58% per year, which means it is significantly lagging earnings growth.お知らせ • Sep 10EirGenix Inc. Appoints Po-Chih Chen as Remuneration CommitteeEirGenix Inc. announced the appointment of Po-Chih Chen as Remuneration Committee, effective from September 8, 2022.Reported Earnings • Aug 16Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2022 results: EPS: NT$0.02 (up from NT$0.65 loss in 2Q 2021). Revenue: NT$336.6m (down 9.6% from 2Q 2021). Net income: NT$6.42m (up NT$154.1m from 2Q 2021). Profit margin: 1.9% (up from net loss in 2Q 2021). The move to profitability was driven by lower expenses. Revenue missed analyst estimates by 31%. Earnings per share (EPS) exceeded analyst estimates. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has only increased by 46% per year, which means it is significantly lagging earnings growth.お知らせ • Jun 11+ 1 more updateEirGenix Inc. Announces Board AppointmentsEirGenix Inc. announced that at its Annual Shareholders' Meeting held on June 10, 2022, elected Jih-Luh Tang, Hsueh-Yen Ku to the Board of Directors and Po-Chih Chen as Independent Director.Reported Earnings • May 16First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: EPS: NT$0.05 (up from NT$1.12 loss in 1Q 2021). Revenue: NT$361.5m (up 48% from 1Q 2021). Net income: NT$13.9m (up NT$243.9m from 1Q 2021). Profit margin: 3.8% (up from net loss in 1Q 2021). The move to profitability was primarily driven by higher revenue. Revenue missed analyst estimates by 39%. Earnings per share (EPS) also missed analyst estimates by 92%. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth.Price Target Changed • Apr 27Price target decreased to NT$129Down from NT$156, the current price target is an average from 2 analysts. New target price is 41% above last closing price of NT$91.00. Stock is down 33% over the past year. The company is forecast to post earnings per share of NT$1.18 next year compared to a net loss per share of NT$0.18 last year.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 7 non-independent directors. Independent Director Ming-Thaur Chang was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 03Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: NT$0.18 loss per share (up from NT$5.41 loss in FY 2020). Revenue: NT$1.70b (up 58% from FY 2020). Net loss: NT$42.6m (loss narrowed 96% from FY 2020). Revenue exceeded analyst estimates by 1.0%. Earnings per share (EPS) missed analyst estimates by 5.3%. Over the next year, revenue is forecast to grow 32%, compared to a 38% growth forecast for the pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 33% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Mar 30EirGenix Inc. Announces Replacement of Representative of Juristic Person as DirectorEirGenix Inc. appointed Kao, Wei-Feng Senior Technical Specialist, National Development Council as Representative of Juristic Person as Director in place of Lin, Jing-Jer, effective April 18, 2022.Price Target Changed • Mar 19Price target decreased to NT$129Down from NT$156, the current price target is an average from 2 analysts. New target price is 36% above last closing price of NT$94.30. Stock is up 6.8% over the past year. The company is forecast to post a net loss per share of NT$0.19 next year compared to a net loss per share of NT$5.41 last year.お知らせ • Feb 07EirGenix Inc. Officially Submitts for Phase I Pkbiosimilarity Clinical Study of Developmental Product EG1206A (Proposed Pertuzumab Biosimilar) in EuropeEirGenix submitted for the Phase I PK biosimilarity clinical study in healthy volunteer's (EGC101, Eudra CT-NR. 2021-006769-40) its clinical trial application of developmental product EG1206A (proposed Pertuzumab biosimilar) to the agency of the German National Competent Authority and the local Ethic Committee on 28th Jan 2022 (CET).Reported Earnings • Nov 15Third quarter 2021 earnings released: EPS NT$1.36 (vs NT$0.34 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: NT$656.6m (up 67% from 3Q 2020). Net income: NT$332.1m (up NT$401.9m from 3Q 2020). Profit margin: 51% (up from net loss in 3Q 2020). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 49% per year, which means it is well ahead of earnings.お知らせ • Sep 24EirGenix Inc. announced that it expects to receive TWD 2.51625 billion in funding from Foxconn Technology Co., Ltd.EirGenix Inc. announced that it has signed a letter of intent for a private placement of 27,500,000 shares at a price of TWD 91.5 per share for a gross proceeds of TWD 2,516,250,000 on September 22, 2021. The transaction will include participation from new investor Foxconn Technology Co., Ltd. for 9.21% stake in the company. The transaction was approved by the shareholders of the company.Reported Earnings • Aug 15Second quarter 2021 earnings released: NT$0.65 loss per share (vs NT$1.74 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: NT$372.4m (up 77% from 2Q 2020). Net loss: NT$147.7m (loss narrowed 55% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has increased by 57% per year, which means it is well ahead of earnings.Reported Earnings • May 18First quarter 2021 earnings released: NT$1.11 loss per share (vs NT$2.06 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: NT$244.8m (up 5.6% from 1Q 2020). Net loss: NT$230.1m (loss narrowed 34% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has increased by 74% per year, which means it is well ahead of earnings.Major Estimate Revision • Apr 13Consensus EPS estimates fall to -NT$3.41The consensus outlook for earnings per share (EPS) in 2021 has deteriorated. 2021 revenue forecast decreased from NT$1.77b to NT$1.74b. Losses expected to increase from -NT$2.84 to -NT$3.41. Life Sciences industry in Taiwan expected to see average net income growth of 31% next year. Consensus price target of NT$122 unchanged from last update. Share price rose 36% to NT$160 over the past week.分析記事 • Apr 08Market Sentiment Around Loss-Making EirGenix Inc. (GTSM:6589)With the business potentially at an important milestone, we thought we'd take a closer look at EirGenix Inc.'s...Reported Earnings • Mar 27Full year 2020 earnings released: NT$5.41 loss per share (vs NT$5.39 loss in FY 2019)The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2020 results: Revenue: NT$1.07b (up 125% from FY 2019). Net loss: NT$1.04b (loss widened 21% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has increased by 51% per year, which means it is well ahead of earnings.分析記事 • Mar 03Is EirGenix (GTSM:6589) Using Debt Sensibly?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Is New 90 Day High Low • Feb 19New 90-day high: NT$54.20The company is up 5.0% from its price of NT$51.70 on 20 November 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 29% over the same period.Is New 90 Day High Low • Jan 22New 90-day low: NT$39.05The company is down 32% from its price of NT$57.30 on 23 October 2020. The Taiwanese market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 37% over the same period.分析記事 • Jan 07Should EirGenix (GTSM:6589) Be Disappointed With Their 73% Profit?Some EirGenix Inc. ( GTSM:6589 ) shareholders are probably rather concerned to see the share price fall 31% over the...Is New 90 Day High Low • Jan 04New 90-day low: NT$44.35The company is down 30% from its price of NT$63.00 on 07 October 2020. The Taiwanese market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 28% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Dec 09New 90-day low: NT$49.15The company is down 22% from its price of NT$62.80 on 11 September 2020. The Taiwanese market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Analyst Estimate Surprise Post Earnings • Nov 14Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 41%. Earnings per share (EPS) missed analyst estimates by 69%. Over the next year, revenue is forecast to grow 128%, compared to a 32% growth forecast for the Life Sciences industry in Taiwan.Reported Earnings • Nov 14Third quarter 2020 earnings released: NT$0.34 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: NT$392.5m (up 338% from 3Q 2019). Net loss: NT$69.8m (loss narrowed 77% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Nov 01New 90-day low: NT$52.50The company is down 7.0% from its price of NT$56.40 on 03 August 2020. The Taiwanese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.株主還元6589TW Life SciencesTW 市場7D-2.0%-1.9%2.6%1Y-31.3%-5.6%94.7%株主還元を見る業界別リターン: 6589過去 1 年間で-5.6 % の収益を上げたTW Life Sciences業界を下回りました。リターン対市場: 6589は、過去 1 年間で94.7 % のリターンを上げたTW市場を下回りました。価格変動Is 6589's price volatile compared to industry and market?6589 volatility6589 Average Weekly Movement5.5%Life Sciences Industry Average Movement5.3%Market Average Movement6.2%10% most volatile stocks in TW Market12.2%10% least volatile stocks in TW Market2.5%安定した株価: 6589 、 TW市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 6589の 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト20121,000Lee-Cheng Liuwww.eirgenix.comEirGenix Inc.は開発・製造受託会社として台湾および海外で事業を展開。同社は、細胞株開発、プロセス開発、分析・品質管理、cGMP製造哺乳類・微生物系、抗体薬物複合体サービスを提供している。また、がん治療を適応症とし、現在生物製剤承認申請中のトラスツズマブ・バイオシミラーであるEG12014/EGI014、がん治療を適応症とし、現在フェーズI段階にあるペルツズマブ・バイオシミラーであるEG1206A、がん治療を適応症とし、現在前臨床段階にあるEG13074の開発にも携わっている；前臨床段階にある抗体薬物複合体であるTSY0110（EG12043）、前臨床段階にあるがん治療適応のベバシズマブのバイオシミラーであるEG12021、前臨床段階にあるバイオシミラーであるEG62054。また、covid-19抗原迅速検査薬、CRM197キャリアプロテインEG74032の製造・販売も行っている。同社は2012年に設立され、台湾の新北市に本社を置いている。もっと見るEirGenix Inc. 基礎のまとめEirGenix の収益と売上を時価総額と比較するとどうか。6589 基礎統計学時価総額NT$13.23b収益（TTM）-NT$745.70m売上高(TTM)NT$1.13b11.7xP/Sレシオ-17.7xPER（株価収益率6589 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計6589 損益計算書（TTM）収益NT$1.13b売上原価NT$890.04m売上総利益NT$241.63mその他の費用NT$987.33m収益-NT$745.70m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-2.46グロス・マージン21.35%純利益率-65.89%有利子負債／自己資本比率12.2%6589 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 10:59終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋EirGenix Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Hengyu FuMasterlink Securities Investment Advisory
Reported Earnings • May 15First quarter 2026 earnings released: NT$0.47 loss per share (vs NT$0.52 loss in 1Q 2025)First quarter 2026 results: NT$0.47 loss per share (improved from NT$0.52 loss in 1Q 2025). Revenue: NT$308.4m (up 70% from 1Q 2025). Net loss: NT$142.2m (loss narrowed 9.5% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Mar 14Full year 2025 earnings released: NT$2.51 loss per share (vs NT$2.28 loss in FY 2024)Full year 2025 results: NT$2.51 loss per share (further deteriorated from NT$2.28 loss in FY 2024). Revenue: NT$1.01b (flat on FY 2024). Net loss: NT$760.6m (loss widened 8.9% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 23% per year whereas the company’s share price has fallen by 20% per year.
お知らせ • Mar 10EirGenix Inc., Annual General Meeting, May 29, 2026EirGenix Inc., Annual General Meeting, May 29, 2026. Location: 2 floor no,8, sec.2 sheng i rd., jhubei city, hsinchu county Taiwan
New Risk • Nov 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.5% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change).
Reported Earnings • Nov 15Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2025 results: NT$0.20 loss per share (improved from NT$0.84 loss in 3Q 2024). Revenue: NT$229.0m (down 7.7% from 3Q 2024). Net loss: NT$60.3m (loss narrowed 77% from 3Q 2024). Revenue missed analyst estimates by 23%. Earnings per share (EPS) exceeded analyst estimates by 67%. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
Reported Earnings • Aug 17Second quarter 2025 earnings: EPS and revenues miss analyst expectationsSecond quarter 2025 results: NT$1.23 loss per share (further deteriorated from NT$0.72 loss in 2Q 2024). Revenue: NT$230.6m (down 6.4% from 2Q 2024). Net loss: NT$370.8m (loss widened 68% from 2Q 2024). Revenue missed analyst estimates by 7.4%. Earnings per share (EPS) also missed analyst estimates by 137%. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.
Reported Earnings • May 15First quarter 2026 earnings released: NT$0.47 loss per share (vs NT$0.52 loss in 1Q 2025)First quarter 2026 results: NT$0.47 loss per share (improved from NT$0.52 loss in 1Q 2025). Revenue: NT$308.4m (up 70% from 1Q 2025). Net loss: NT$142.2m (loss narrowed 9.5% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Mar 14Full year 2025 earnings released: NT$2.51 loss per share (vs NT$2.28 loss in FY 2024)Full year 2025 results: NT$2.51 loss per share (further deteriorated from NT$2.28 loss in FY 2024). Revenue: NT$1.01b (flat on FY 2024). Net loss: NT$760.6m (loss widened 8.9% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 23% per year whereas the company’s share price has fallen by 20% per year.
お知らせ • Mar 10EirGenix Inc., Annual General Meeting, May 29, 2026EirGenix Inc., Annual General Meeting, May 29, 2026. Location: 2 floor no,8, sec.2 sheng i rd., jhubei city, hsinchu county Taiwan
New Risk • Nov 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.5% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change).
Reported Earnings • Nov 15Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2025 results: NT$0.20 loss per share (improved from NT$0.84 loss in 3Q 2024). Revenue: NT$229.0m (down 7.7% from 3Q 2024). Net loss: NT$60.3m (loss narrowed 77% from 3Q 2024). Revenue missed analyst estimates by 23%. Earnings per share (EPS) exceeded analyst estimates by 67%. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
Reported Earnings • Aug 17Second quarter 2025 earnings: EPS and revenues miss analyst expectationsSecond quarter 2025 results: NT$1.23 loss per share (further deteriorated from NT$0.72 loss in 2Q 2024). Revenue: NT$230.6m (down 6.4% from 2Q 2024). Net loss: NT$370.8m (loss widened 68% from 2Q 2024). Revenue missed analyst estimates by 7.4%. Earnings per share (EPS) also missed analyst estimates by 137%. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.
Major Estimate Revision • Jun 21Consensus revenue estimates fall by 39%The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from NT$2.42b to NT$1.49b. Forecast losses increased from -NT$0.68 to -NT$0.90 per share. Life Sciences industry in Taiwan expected to see average net income growth of 19% next year. Consensus price target down from NT$128 to NT$117. Share price rose 5.5% to NT$65.50 over the past week.
Price Target Changed • Jun 21Price target decreased by 8.6% to NT$117Down from NT$128, the current price target is an average from 2 analysts. New target price is 78% above last closing price of NT$65.50. Stock is down 24% over the past year. The company is forecast to post a net loss per share of NT$0.90 next year compared to a net loss per share of NT$2.28 last year.
Reported Earnings • May 15First quarter 2025 earnings released: NT$0.52 loss per share (vs NT$0.34 loss in 1Q 2024)First quarter 2025 results: NT$0.52 loss per share (further deteriorated from NT$0.34 loss in 1Q 2024). Revenue: NT$181.9m (down 17% from 1Q 2024). Net loss: NT$157.1m (loss widened 51% from 1Q 2024). Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance.
お知らせ • May 06EirGenix Inc. to Report Q1, 2025 Results on May 13, 2025EirGenix Inc. announced that they will report Q1, 2025 results at 2:30 PM, Taipei Standard Time on May 13, 2025
お知らせ • Apr 07+ 1 more updateEirGenix Inc. Officially Submits the Phase III Clinical Trial Application of EG1206A to the Health Authority of GeorgiaEirGenix has officially submitted the Phase III clinical trial application of EG1206A to the health authority of Mexico. New drug name or code: EG1206A (pertuzumab biosimilar). Indication: Early breast cancer (EBC) and metastatic breast cancer (MBC). Planned development stages: (1) IND: Completed, (2) Phase I: Completed, (3) Phase III: Multi countries, multi centers study, (4) BLA/MAA: Not yet started. Current development stage: (1) Application submission/approval/disapproval/each of clinical trials (include interim analysis): USFDA & TFDA agreed EirGenix to proceed the Phase III clinical trial of EG1206A (pertuzumab biosimilar). EirGenix has officially submitted the Phase III clinical trial application of EG1206A to the regulatory authority of Mexico-COFEPRIS (Comision Federal para la Proteccion contra Riesgos Sanitarios). After obtaining official approval or the results of statistically significant sense, the future strategy: After completing the Phase III clinical trial for the developmental product EG1206A (pertuzumab biosimilar), the Company will submit a marketing application to regulatory agency. Accumulated investment expenditure incurred: The information may affect the licensing deal during the future international negotiation. To protect the rights and interests of the Company and investors, it will not be disclosed publicly. Upcoming development plan: (1) Estimated date of completion: The actual completion time will depend on the regulatory agency review and the progress of trial enrollment. The Company will disclose relevant information in accordance with regulations. Market situation: According to Roche's annual report of FY2024, global sales of Perjeta totaled CHF 3.616 billion (around USD 4.003 billion) in FY2024.
Reported Earnings • Mar 19Full year 2024 earnings: EPS and revenues exceed analyst expectationsFull year 2024 results: NT$2.28 loss per share (improved from NT$3.00 loss in FY 2023). Revenue: NT$1.01b (down 1.3% from FY 2023). Net loss: NT$698.3m (loss narrowed 24% from FY 2023). Revenue exceeded analyst estimates by 13%. Earnings per share (EPS) also surpassed analyst estimates by 13%. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance.
お知らせ • Mar 13+ 2 more updatesEirGenix Inc., Annual General Meeting, Jun 13, 2025EirGenix Inc., Annual General Meeting, Jun 13, 2025. Location: 1 floor no,102 ln.169, k`ang ning st., sijhih district, new taipei city Taiwan
お知らせ • Mar 05EirGenix Inc. to Report Fiscal Year 2024 Results on Mar 12, 2025EirGenix Inc. announced that they will report fiscal year 2024 results on Mar 12, 2025
New Risk • Jan 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (NT$454m net loss in 2 years). Share price has been volatile over the past 3 months (6.1% average weekly change).
お知らせ • Jan 24USFDA Issues Study May Proceed Letter to EirGenix for the Phase III Clinical Trial of Developmental Product Eg1206a (Pertuzumab Biosimilar)EirGenix Inc. announced that it has issued a study may proceed letter to EirGenix for the Phase III clinical trial of EG1206A (pertuzumab biosimilar). Indication: Early breast cancer (EBC) and metastatic breast cancer (MBC). Planned development stages: IND: Completed (2) Phase I: Completed Phase III: The USFDA has issued a study may proceed Letter to EirGenix for The Phase III clinical trial of the developmental product EG1206A (pertizumab biosimilar). BLA/MAA: Not yet started. Current development stage: Application submission/approval/approval/disapproval/each of clinical trials (include interim analysis): The USFDA has issuing a study may proceed letter toEirGenix for the Phase II clinical trial of the developmental productEG1206A (pertuzUMab biosimilar). Once disapproved by competent authority or each of clinical trials (include interim analysis) results less than statistically significant sense, the risks & the associated measures the Company may occur: After completing the Phase III clinical trial of the Development product EG1206A (expertuzumab biosimilar). The Company will submit a marketing application to regulatory agency (4) Accumulated investment expenditure incurred: The information may affect the licensing deal during the future international negotiation. To protect the rights and interests of the Company and investors, it will not be disclosed publicly. Upcoming development plan: Estimated date of completion: The actual completion time will depend on the regulatory agency review and the progress of trial enrollment. The Company will disclose relevant information in accordance with regulations. Estimated responsibilities: None.
お知らせ • Jan 06EirGenix, Inc. Officially Submits NDA for the Biosimilar Drug EIRGASUN of 420 Mg Lyophilized Powder for Intraous Administration to the TFDAEirGenix Inc., has officially submitted NDA for the biosimilar drug EIRGASUN of 420 mg lyophilized powder for intravenous administration to the TFDA. New drug name or code: EG12014 (EIRGASUN) (trastuzumab biosimilar). Indication: The treatment of HER2 overexpressing early breast cancer, metastatic breast cancer and metastatic gastric cancer. Planned development stages: This application pertains to the registration of a previously approved biological product with different strength and packaging from different manufacturing sites. The drug product manufacturing facility is Formosa Laboratories Inc. and TFDA is currently reviewing status after the GMP inspection. Current development stage: Application submission/approval/disapproval/each of clinical trials (include interim analysis): Submit New Drug Application (NDA) for EIRGASUN 420 mg lyophilized powder for intravenous administration to the Taiwan Food and Drug Administration (TFDA). After obtaining official approval or the results of statistically significant sense, the future strategy: Once EG12014 420 mg lyophilized powder for intravenous administration is approved in Taiwan, it will have a positive impact on EirGenix's business operation in the future. Accumulated investment expenditure incurred: It was agreed not to disclose this information publicly to protect the company and investors' rights according to the signed confidentiality agreement with Sandoz AG. Upcoming development plan: Estimated date of completion: The review time is based on the process of TFDA. The actual review and approval time are the decision of the TFDA and are subject to the official notification of the TFDA.
お知らせ • Dec 26EirGenix Inc. Officially Submits the Phase III Clinical Trial Application for the Developmental Product EG1206A (pertuzumab Biosimilar) in US FDAEirGenix has officially submitted the Phase III clinical trial application for the developmental product EG1206A (pertuzumab biosimilar) in US FDA. Early breast cancer (EBC) and metastatic breast cancer (MBC) 4.Planned development stages: (1) IND: Completed (2) Phase I: Completed (3) Phase III: EirGenix has officially submitted Phase III clinical trial application in US FDA. (4) BLA/MAA: Not yet started. 5.Current development stage: (1)Application submission/approval/disapproval/each of clinical trials (include interim analysis): EirGenix has officially submitted Phase III clinical trial application in US FDA. (2)Once disapproved by competent authority or each of clinical trials (include interim analysis) results less than statistically significant sense, the risks & the associated measures the Company may occur: N/A (3)After obtaining official approval or the results of statistically significant sense, the future strategy: After completing the Phase III clinical trial for the developmental product EG1206A (pertuzumab biosimilar), the company will submit a marketing application to regulatory agency.
New Risk • Dec 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (NT$480m net loss in 2 years). Share price has been volatile over the past 3 months (6.3% average weekly change).
Major Estimate Revision • Dec 12Consensus revenue estimates fall by 16%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from NT$1.07b to NT$895.0m. Forecast losses increased from -NT$1.94 to -NT$2.61 per share. Life Sciences industry in Taiwan expected to see average net income growth of 50% next year. Consensus price target down from NT$120 to NT$115. Share price fell 20% to NT$73.50 over the past week.
Reported Earnings • Nov 15Third quarter 2024 earnings: EPS exceeds analyst expectationsThird quarter 2024 results: NT$0.84 loss per share (further deteriorated from NT$0.37 loss in 3Q 2023). Revenue: NT$248.2m (up 17% from 3Q 2023). Net loss: NT$256.1m (loss widened 129% from 3Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.3%. Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.
お知らせ • Nov 05EirGenix Inc. to Report Q3, 2024 Results on Nov 12, 2024EirGenix Inc. announced that they will report Q3, 2024 results on Nov 12, 2024
Reported Earnings • Aug 17Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2024 results: NT$0.72 loss per share (further deteriorated from NT$0.64 loss in 2Q 2023). Revenue: NT$246.4m (up 78% from 2Q 2023). Net loss: NT$220.6m (loss widened 14% from 2Q 2023). Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) missed analyst estimates by 2.9%. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
お知らせ • Aug 01EirGenix Inc. to Report Q2, 2024 Results on Aug 08, 2024EirGenix Inc. announced that they will report Q2, 2024 results on Aug 08, 2024
Major Estimate Revision • May 30Consensus revenue estimates fall by 28%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from NT$2.29b to NT$1.64b. Forecast loss of -NT$1.00, down from profit of NT$1.09 per share profit previously. Life Sciences industry in Taiwan expected to see average net income growth of 39% next year. Consensus price target down from NT$133 to NT$113. Share price was steady at NT$79.10 over the past week.
Breakeven Date Change • May 29No longer forecast to breakevenThe analyst covering EirGenix no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of NT$65.0m in 2024. New forecast suggests the company will make a loss of NT$413.0m in 2025.
Reported Earnings • May 18First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2024 results: NT$0.34 loss per share (improved from NT$0.67 loss in 1Q 2023). Revenue: NT$219.7m (up 1.6% from 1Q 2023). Net loss: NT$104.0m (loss narrowed 49% from 1Q 2023). Revenue missed analyst estimates by 3.6%. Earnings per share (EPS) exceeded analyst estimates by 42%. Revenue is forecast to grow 47% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
お知らせ • May 02EirGenix Inc. to Report Q1, 2024 Results on May 09, 2024EirGenix Inc. announced that they will report Q1, 2024 results on May 09, 2024
Breakeven Date Change • Apr 23Forecast breakeven date pushed back to 2025The analyst covering EirGenix previously expected the company to break even in 2024. New forecast suggests the company will make a profit of NT$413.0m in 2025. Average annual earnings growth of 144% is required to achieve expected profit on schedule.
Reported Earnings • Mar 26Full year 2023 earnings: EPS misses analyst expectationsFull year 2023 results: NT$3.00 loss per share (further deteriorated from NT$0.38 loss in FY 2022). Revenue: NT$1.02b (down 31% from FY 2022). Net loss: NT$915.2m (loss widened NT$799.7m from FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 67%. Revenue is forecast to grow 45% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
お知らせ • Mar 09EirGenix Inc., Annual General Meeting, May 30, 2024EirGenix Inc., Annual General Meeting, May 30, 2024, at 09:30 Taipei Standard Time. Location: International Conference Hall, R&D Center, Hsinchu Biomedical Park 2F, No. 8, Sec. 2, Shengyi Rd., Zhubei City, Hsinchu County Zhubei Taiwan Agenda: To consider Report the business results of 2023; to Audit Committee’s review report; to The 2023 implementation report for the sound business plan; to Amendment to the Regulations Governing Procedure for Board of Directors Meetings; to Discontinue the Private Security Offering Approved by 2023 Shareholders' Meeting; to Remuneration policy for the directors of 2023; to Accept 2023 financial statements and business report; to Ratification of the 2023 deficit offset proposal; and to consider other matters if any.
Major Estimate Revision • Feb 06Consensus revenue estimates fall by 18%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from NT$1.24b to NT$1.02b. Forecast losses increased from -NT$0.89 to -NT$1.80 per share. Life Sciences industry in Taiwan expected to see average net income growth of 28% next year. Consensus price target down from NT$155 to NT$133. Share price was steady at NT$91.80 over the past week.
Price Target Changed • Feb 05Price target decreased by 16% to NT$133Down from NT$158, the current price target is an average from 2 analysts. New target price is 44% above last closing price of NT$91.80. Stock is down 23% over the past year. The company is forecast to post a net loss per share of NT$1.80 next year compared to a net loss per share of NT$0.38 last year.
お知らせ • Nov 23EirGenix Inc.'s Breast Cancer Biosimilar Receives Marketing Authorization by ECEirGenix Inc. announced that its trastuzumab biosimilar medicine (EG12014) which their commercial partner Sandoz plans to commercialize (150 mg, for intravenous use) had received a marketing authorization from the European Commission (EC). The marketing authorization in the EU will cover the treatment of human epidermal growth factor receptor 2 positive (HER2-positive) breast cancer and metastatic gastric cancers, which are the same indications approved by the EC for the reference biologic, Herceptin(R). Sandoz AG and EirGenix signed a license agreement in April 2019. Under this agreement, EirGenix Inc. will remain responsible for the development and manufacturing of trastuzumab while Sandoz will hold the rights to commercialize the medicine upon approval in the global market (excluding Taiwan, China, Russia, and some Asian countries). Breast and gastric cancers are among the most frequently occurring in Europe, and combined, are responsible for nearly 200,000 deaths annually. Biosimilars have enormous potential to improve cancer care by substantially increasing access to these critical medicines. The impact of both breast and gastric cancer in Europe is significant. Each year, over 355,000 women are diagnosed with breast cancer, and with 92,000 deaths per year, it is the number one cause of cancer death among women. Gastric cancer is the sixth most common of all cancer types and with 107,000 deaths annually it is the fourth most common cause of cancer-related death in Europe. In up to 20% of breast cancers and up to 30% of gastric cancers diagnosed, a HER2 protein overexpression (or HER2 gene amplification) is detected resulting in an uncontrollable growth and division of cells. HER2 cancers are particularly aggressive cancer types that respond well to targeted treatment. The authorisation of EG12014 in Europe expands access to a vital, high-quality treatment for breast and gastric cancers helping to ease the burden of these diseases on patients and delivering important savings for healthcare systems to ensure sustainability. EirGenix's trastuzumab bios biosimilar drug (EG12014) (150 mg lyophilized powder for injection) also received market approval by TFDA in June. The application of the health insurance pricing was approved by the National Health Insurance Administration under the Ministry of Health and Welfare in mid-September, paving the way for the formal launch of the product in Taiwan. EirGenix develops a series of HER2-positive breast cancer product combinations, including the second- generation HER2-positive targeted antibody drug Perjeta(R) (Pertuzumab), which are continuously advancing into the Phase III clinical trial. With the successful market introduction of the products, further market expansion and strengthening of the product's international competitive advantage will be realized.
Reported Earnings • Nov 15Third quarter 2023 earnings: EPS exceeds analyst expectationsThird quarter 2023 results: NT$0.37 loss per share (further deteriorated from NT$0.091 loss in 3Q 2022). Revenue: NT$211.5m (down 42% from 3Q 2022). Net loss: NT$111.7m (loss widened 305% from 3Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 25%. Revenue is forecast to grow 51% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth.
Breakeven Date Change • Nov 15The 2 analysts covering EirGenix previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of NT$113.0m in 2024.
お知らせ • Sep 20National Health Insurance Administration Approves EirGenix Inc.'S Biosimilar, Eirgasun Vial 150 Mg to Be Enrolled in the Reimbursement SystemEirGenix Inc.'s biosimilar, Eirgasun vial 150 mg, has been approved by National Health Insurance Administration, Ministry of Health and Welfare to be enrolled in the reimbursement system, it is officially effective from October 1, 2023. Usage: The treatment of HER2 overexpressing early breast cancer, metastatic breast cancer, and metastatic gastric cancer. The price paid is TWD 11,323 per vial at the current market price.
Reported Earnings • Aug 10Second quarter 2023 earnings: EPS and revenues miss analyst expectationsSecond quarter 2023 results: NT$0.64 loss per share (down from NT$0.021 profit in 2Q 2022). Revenue: NT$138.3m (down 59% from 2Q 2022). Net loss: NT$194.1m (down NT$200.5m from profit in 2Q 2022). Revenue missed analyst estimates by 63%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 66% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.
Price Target Changed • Jun 09Price target decreased by 7.5% to NT$172Down from NT$186, the current price target is an average from 2 analysts. New target price is 57% above last closing price of NT$110. Stock is up 25% over the past year. The company is forecast to post a net loss per share of NT$0.13 next year compared to a net loss per share of NT$0.38 last year.
Reported Earnings • Mar 21Full year 2022 earnings: Revenues and EPS in line with analyst expectationsFull year 2022 results: NT$0.38 loss per share (further deteriorated from NT$0.17 loss in FY 2021). Revenue: NT$1.48b (down 13% from FY 2021). Net loss: NT$115.5m (loss widened 171% from FY 2021). Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has only increased by 64% per year, which means it is significantly lagging earnings growth.
Price Target Changed • Mar 15Price target decreased by 9.8% to NT$175Down from NT$194, the current price target is an average from 2 analysts. New target price is 55% above last closing price of NT$113. Stock is up 23% over the past year. The company is forecast to post a net loss per share of NT$0.18 next year compared to a net loss per share of NT$0.18 last year.
お知らせ • Jan 12EirGenix Inc. Announces Executive ChangesEirGenix Inc. announced that Chun-Fu Lu, Chairman, Foxconn Technology Co. Ltd., has replaced Jih-Luh Tang as Representative of Juristic Person as Director, effective January 10, 2023.
Breakeven Date Change • Dec 31Forecast breakeven date pushed back to 2023The 2 analysts covering EirGenix previously expected the company to break even in 2022. New consensus forecast suggests the company will make a profit of NT$710.0m in 2023. Average annual earnings growth of 105% is required to achieve expected profit on schedule.
お知らせ • Dec 29Eirgenix Inc. Announces Establishment of Corporate Governance CommitteeEirGenix Inc. announced the establishment of the company's Corporate Governance Committee with Lee-Cheng Liu: President & CEO, EirGenix, Inc; Ming-Thaur Chang: Independent Director, DBS Bank (Taiwan) Ltd.; Fu-Shiow Yin: Independent Director, Foresee Pharmaceuticals Co. Ltd.; Ming-Shen Chen: Professor of Finance at National Taiwan University.; and Po-Chih Chen: Senior Advisors to the President, effective December 28, 2022. Mr. Ming-Shen Chen is the chairman of first term Corporate Governance Committee.
Price Target Changed • Nov 29Price target increased to NT$169Up from NT$156, the current price target is an average from 2 analysts. New target price is 27% above last closing price of NT$133. Stock is up 20% over the past year. The company is forecast to post earnings per share of NT$0.02 next year compared to a net loss per share of NT$0.18 last year.
Reported Earnings • Nov 16Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: NT$0.09 loss per share (down from NT$1.36 profit in 3Q 2021). Revenue: NT$361.6m (down 45% from 3Q 2021). Net loss: NT$27.6m (down 108% from profit in 3Q 2021). Revenue exceeded analyst estimates by 7.3%. Earnings per share (EPS) also surpassed analyst estimates by 70%. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has only increased by 68% per year, which means it is significantly lagging earnings growth.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 6 non-independent directors. Independent Director Po-Chih Chen was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 13Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: NT$0.09 loss per share (down from NT$1.36 profit in 3Q 2021). Revenue: NT$361.6m (down 45% from 3Q 2021). Net loss: NT$27.6m (down 108% from profit in 3Q 2021). Revenue exceeded analyst estimates by 7.3%. Earnings per share (EPS) also surpassed analyst estimates by 70%. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has only increased by 58% per year, which means it is significantly lagging earnings growth.
お知らせ • Sep 10EirGenix Inc. Appoints Po-Chih Chen as Remuneration CommitteeEirGenix Inc. announced the appointment of Po-Chih Chen as Remuneration Committee, effective from September 8, 2022.
Reported Earnings • Aug 16Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2022 results: EPS: NT$0.02 (up from NT$0.65 loss in 2Q 2021). Revenue: NT$336.6m (down 9.6% from 2Q 2021). Net income: NT$6.42m (up NT$154.1m from 2Q 2021). Profit margin: 1.9% (up from net loss in 2Q 2021). The move to profitability was driven by lower expenses. Revenue missed analyst estimates by 31%. Earnings per share (EPS) exceeded analyst estimates. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has only increased by 46% per year, which means it is significantly lagging earnings growth.
お知らせ • Jun 11+ 1 more updateEirGenix Inc. Announces Board AppointmentsEirGenix Inc. announced that at its Annual Shareholders' Meeting held on June 10, 2022, elected Jih-Luh Tang, Hsueh-Yen Ku to the Board of Directors and Po-Chih Chen as Independent Director.
Reported Earnings • May 16First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: EPS: NT$0.05 (up from NT$1.12 loss in 1Q 2021). Revenue: NT$361.5m (up 48% from 1Q 2021). Net income: NT$13.9m (up NT$243.9m from 1Q 2021). Profit margin: 3.8% (up from net loss in 1Q 2021). The move to profitability was primarily driven by higher revenue. Revenue missed analyst estimates by 39%. Earnings per share (EPS) also missed analyst estimates by 92%. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth.
Price Target Changed • Apr 27Price target decreased to NT$129Down from NT$156, the current price target is an average from 2 analysts. New target price is 41% above last closing price of NT$91.00. Stock is down 33% over the past year. The company is forecast to post earnings per share of NT$1.18 next year compared to a net loss per share of NT$0.18 last year.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 7 non-independent directors. Independent Director Ming-Thaur Chang was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 03Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: NT$0.18 loss per share (up from NT$5.41 loss in FY 2020). Revenue: NT$1.70b (up 58% from FY 2020). Net loss: NT$42.6m (loss narrowed 96% from FY 2020). Revenue exceeded analyst estimates by 1.0%. Earnings per share (EPS) missed analyst estimates by 5.3%. Over the next year, revenue is forecast to grow 32%, compared to a 38% growth forecast for the pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 33% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Mar 30EirGenix Inc. Announces Replacement of Representative of Juristic Person as DirectorEirGenix Inc. appointed Kao, Wei-Feng Senior Technical Specialist, National Development Council as Representative of Juristic Person as Director in place of Lin, Jing-Jer, effective April 18, 2022.
Price Target Changed • Mar 19Price target decreased to NT$129Down from NT$156, the current price target is an average from 2 analysts. New target price is 36% above last closing price of NT$94.30. Stock is up 6.8% over the past year. The company is forecast to post a net loss per share of NT$0.19 next year compared to a net loss per share of NT$5.41 last year.
お知らせ • Feb 07EirGenix Inc. Officially Submitts for Phase I Pkbiosimilarity Clinical Study of Developmental Product EG1206A (Proposed Pertuzumab Biosimilar) in EuropeEirGenix submitted for the Phase I PK biosimilarity clinical study in healthy volunteer's (EGC101, Eudra CT-NR. 2021-006769-40) its clinical trial application of developmental product EG1206A (proposed Pertuzumab biosimilar) to the agency of the German National Competent Authority and the local Ethic Committee on 28th Jan 2022 (CET).
Reported Earnings • Nov 15Third quarter 2021 earnings released: EPS NT$1.36 (vs NT$0.34 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: NT$656.6m (up 67% from 3Q 2020). Net income: NT$332.1m (up NT$401.9m from 3Q 2020). Profit margin: 51% (up from net loss in 3Q 2020). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 49% per year, which means it is well ahead of earnings.
お知らせ • Sep 24EirGenix Inc. announced that it expects to receive TWD 2.51625 billion in funding from Foxconn Technology Co., Ltd.EirGenix Inc. announced that it has signed a letter of intent for a private placement of 27,500,000 shares at a price of TWD 91.5 per share for a gross proceeds of TWD 2,516,250,000 on September 22, 2021. The transaction will include participation from new investor Foxconn Technology Co., Ltd. for 9.21% stake in the company. The transaction was approved by the shareholders of the company.
Reported Earnings • Aug 15Second quarter 2021 earnings released: NT$0.65 loss per share (vs NT$1.74 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: NT$372.4m (up 77% from 2Q 2020). Net loss: NT$147.7m (loss narrowed 55% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has increased by 57% per year, which means it is well ahead of earnings.
Reported Earnings • May 18First quarter 2021 earnings released: NT$1.11 loss per share (vs NT$2.06 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: NT$244.8m (up 5.6% from 1Q 2020). Net loss: NT$230.1m (loss narrowed 34% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has increased by 74% per year, which means it is well ahead of earnings.
Major Estimate Revision • Apr 13Consensus EPS estimates fall to -NT$3.41The consensus outlook for earnings per share (EPS) in 2021 has deteriorated. 2021 revenue forecast decreased from NT$1.77b to NT$1.74b. Losses expected to increase from -NT$2.84 to -NT$3.41. Life Sciences industry in Taiwan expected to see average net income growth of 31% next year. Consensus price target of NT$122 unchanged from last update. Share price rose 36% to NT$160 over the past week.
分析記事 • Apr 08Market Sentiment Around Loss-Making EirGenix Inc. (GTSM:6589)With the business potentially at an important milestone, we thought we'd take a closer look at EirGenix Inc.'s...
Reported Earnings • Mar 27Full year 2020 earnings released: NT$5.41 loss per share (vs NT$5.39 loss in FY 2019)The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2020 results: Revenue: NT$1.07b (up 125% from FY 2019). Net loss: NT$1.04b (loss widened 21% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has increased by 51% per year, which means it is well ahead of earnings.
分析記事 • Mar 03Is EirGenix (GTSM:6589) Using Debt Sensibly?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Is New 90 Day High Low • Feb 19New 90-day high: NT$54.20The company is up 5.0% from its price of NT$51.70 on 20 November 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 29% over the same period.
Is New 90 Day High Low • Jan 22New 90-day low: NT$39.05The company is down 32% from its price of NT$57.30 on 23 October 2020. The Taiwanese market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 37% over the same period.
分析記事 • Jan 07Should EirGenix (GTSM:6589) Be Disappointed With Their 73% Profit?Some EirGenix Inc. ( GTSM:6589 ) shareholders are probably rather concerned to see the share price fall 31% over the...
Is New 90 Day High Low • Jan 04New 90-day low: NT$44.35The company is down 30% from its price of NT$63.00 on 07 October 2020. The Taiwanese market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 28% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Dec 09New 90-day low: NT$49.15The company is down 22% from its price of NT$62.80 on 11 September 2020. The Taiwanese market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Analyst Estimate Surprise Post Earnings • Nov 14Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 41%. Earnings per share (EPS) missed analyst estimates by 69%. Over the next year, revenue is forecast to grow 128%, compared to a 32% growth forecast for the Life Sciences industry in Taiwan.
Reported Earnings • Nov 14Third quarter 2020 earnings released: NT$0.34 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: NT$392.5m (up 338% from 3Q 2019). Net loss: NT$69.8m (loss narrowed 77% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Nov 01New 90-day low: NT$52.50The company is down 7.0% from its price of NT$56.40 on 03 August 2020. The Taiwanese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
